FDA Warns Glenmark Over Temperature Excursions, Gritty Topicals

Firm should have addressed complaints of gritty topicals and compromised container/closures, and its own findings about overheated creams, the US FDA says.

Warning Rubber Stamp
FDA Says Glenmark Still Has Not Addressed Formulation Problems • Source: Shutterstock

The US Food and Drug Administration has hit Glenmark Pharmaceuticals Ltd., Mumbai, India, with a 3 October warning letter for a number of good manufacturing practice violations, including not addressing issues related to product grittiness in its topical creams and for not investigating temperature excursions.

The warning letter followed an inspection at the firm’s site in Baddi, India, following an inspection in April. The FDA...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America